XML 67 R55.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaborative Development Contracts (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Apr. 30, 2025 USD ($) | Nov. 30, 2024 USD ($) performance_obligation | Sep. 30, 2024 USD ($) | Jan. 31, 2022 USD ($) program performance_obligation phenomap candidate | Sep. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | $ 4.5 | $ 4.1 | $ 36.6 | $ 29.0 |
Cost incurred |  |  |  |  | $ 5.6 |  | $ 5.6 |  |
Sanofi | Collaborative Arrangement |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Maximum number of novel small molecule candidates | candidate |  |  |  | 15 |  |  |  |  |
Remaining unearned revenue |  |  |  | $ 100.0 |  |  |  |  |
Revenue recognized | $ 30.0 |  |  |  |  |  |  |  |
Milestone payment received | 7.0 |  |  |  |  |  |  |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation |  | 8 |  |  |  |  |  |  |
Remaining performance obligation revenue |  | $ 152.9 |  |  |  |  |  |  |
Sanofi | Collaborative Arrangement | Research Milestones |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Remaining unearned revenue | 555.0 |  |  |  |  |  |  |  |
Sanofi | Collaborative Arrangement | Development And Regulatory Milestones |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Remaining unearned revenue | $ 1,800.0 |  |  |  |  |  |  |  |
Merck KGaA (Merck) | Collaborative Arrangement |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Remaining unearned revenue |  |  |  |  |  |  |  |  | $ 20.1
Number of performance obligations under the agreement (in performance obligations) | performance_obligation |  | 3 |  |  |  |  |  |  |
Remaining performance obligation revenue |  | $ 20.1 |  |  |  |  |  |  |
Merck KGaA (Merck) | Collaborative Arrangement | Discovery, Development And Sales Milestones |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Remaining unearned revenue |  |  |  |  |  |  |  |  | $ 73.0
Roche and Genentech | Collaborative Arrangement |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Remaining unearned revenue |  |  |  | $ 150.0 |  |  |  |  |
Revenue recognized |  |  | $ 30.0 |  |  |  |  |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation |  |  |  | 3 |  |  |  |  |
Remaining performance obligation revenue |  |  |  | $ 180.0 |  |  |  |  |
Roche and Genentech | Collaborative Arrangement | Phenomaps Creation |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Research project, fees and milestones payments receivable for an option on a lead series |  |  |  | $ 250.0 |  |  |  |  |
Number of eligible phenomaps | phenomap |  |  |  | 16 |  |  |  |  |
Roche and Genentech | Collaborative Arrangement | Phenomaps Raw Images |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Research project, fees and milestones payments receivable for an option on a lead series |  |  |  | $ 250.0 |  |  |  |  |
Number of eligible phenomaps | phenomap |  |  |  | 12 |  |  |  |  |
Roche and Genentech | Collaborative Arrangement | Developed and Commercialized Programs |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Research project, fees and milestones payments receivable for an option on a lead series |  |  |  | $ 300.0 |  |  |  |  |
Number of projects that may be initiated | program |  |  |  | 40 |  |  |  |  |
Roche and Genentech | Collaborative Arrangement | Gastrointestinal Cancer |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation |  |  |  | 1 |  |  |  |  |
Roche and Genentech | Collaborative Arrangement | Neuroscience |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation |  |  |  | 2 |  |  |  |  |

X
- Definition Collaborative Arrangement, Milestone Payment Received + References No definition available. + Details
Name: | rxrx_CollaborativeArrangementMilestonePaymentReceived
Namespace Prefix: | rxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract With Customer, Maximum Accepted Product + References No definition available. + Details
Name: | rxrx_ContractWithCustomerMaximumAcceptedProduct
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract With Customer, Number Of Novel Small Molecule Candidates + References No definition available. + Details
Name: | rxrx_ContractWithCustomerNumberOfNovelSmallMoleculeCandidates
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Number Of Obligations + References No definition available. + Details
Name: | rxrx_RevenuePerformanceObligationNumberOfObligations
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated + References No definition available. + Details
Name: | rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | rxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=rxrx_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_MilestoneTypeAxis=rxrx_ResearchMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_MilestoneTypeAxis=rxrx_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rxrx_MerckKGaAMerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_MilestoneTypeAxis=rxrx_DiscoveryDevelopmentAndSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsCreationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsRawImagesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_DevelopedAndCommercializedProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_GastrointestinalCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |